Merck Partnered with Dragonfly for Development and Commercialization of Immunotherapies for $695M

 Merck Partnered with Dragonfly for Development and Commercialization of Immunotherapies for $695M

Merck Partnered with Dragonfly for Development and Commercialization of Immunotherapies for $695M

Shots:

  • Dragonfly Therapeutics will receive an upfront $695M with milestone and royalties on sales and Merck to get option to license exclusive worldwide IPR rights of products developed using Dragonfly’s TriNKET technology
  • The agreement is focus on developing and providing immunotherapies using TriNKET technology platform to treat solid malignancies
  • TriNKET technology is based on NK cell receptor, is utilized for development of novel therapeutics targeting solid tumor indications

Click here to read full press release/ article | Ref: Prnewsire | Image: Prnewsire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post